
Boris Mankovsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1575966/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	1.3	69
2	Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Research and Clinical Practice, 2022, 186, 109063.	1.1	66
3	Editorial commentary to manuscript "Neural correlates of slower gait in middle-aged persons with childhood-onset type 1 diabetes mellitus: The impact of accelerated brain aging―by Royse et al. Journal of Diabetes and Its Complications, 2022, 36, 108109.	1.2	0
4	Use of Continuous Glucose Monitoring in Patient with Coronary Artery Disease and Type 2 Diabetes Mellitus: Case Report. Ukrainian Journal of Cardiovascular Surgery, 2022, 30, 83-88.	0.0	0
5	A contemporary view on obesity treatment in adults. Reproductive Endocrinology, 2021, , 45-50.	0.0	3
6	Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 185.	2.7	83
7	Diabetes Care at the Times of Transition and COVID-19 Pandemics (Ukrainian Experience). Journal of Diabetes Science and Technology, 2020, 14, 754-755.	1.3	6
8	Factors associated with the onset of major depressive disorder in adults with type 2 diabetes living in 12 different countries: results from the INTERPRET-DD prospective study. Epidemiology and Psychiatric Sciences, 2020, 29, e134.	1.8	15
9	Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs. Cardiovascular Diabetology, 2019, 18, 115.	2.7	9
10	CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle. Diabetes Research and Clinical Practice, 2019, 153, 30-40.	1.1	5
11	The effect of OMEGA-3 polyunsaturated fatty acids on ambulatory blood pressure monitoring parameters in patients with type 2 diabetes mellitus and cardiovascular autonomic neuropathy. Diabetes Mellitus, 2019, 22, 62-69.	0.5	1
12	Prevalence and correlates of depressive disorders in people with Type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and Depression (<scp>INTERPRET</scp> â€ <scp>DD</scp>) study, a collaborative study carried out in 14 countries. Diabetic Medicine, 2018, 35, 760-769.	1.2	103
13	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	6.3	1,179
14	Cognitive functioning and structural brain abnormalities in people with Type 2 diabetes mellitus. Diabetic Medicine, 2018, 35, 1663-1670.	1.2	34
15	Relationship between diabetic retinopathy and cerebral perfusion in type 2 diabetes mellitus. Oftalmologicheskii Zhurnal, 2018, 71, 49-53.	0.0	1
16	Risk factors cardiovascular autonomi c neuropathy in type 2 diabetes mellitus. Endokrynologia, 2018, 23, 309-313.	0.5	0
17	Predictors of response to treatment with actovegin for 6 months in patients with type 2 diabetes and symptomatic polyneuropathy. Journal of Diabetes and Its Complications, 2017, 31, 1181-1187.	1.2	15
18	Characteristics of cognitive function in patients with diabetes mellitus type 1 younger depending transferred hypoglycemic conditions. East European Journal of Neurology, 2017, , 17-21.	0.0	0

BORIS ΜΑΝΚΟΎSKY

#	Article	IF	CITATIONS
19	Relationship between diabetic retinopathy and cognitive impairment in patients with type 2 diabetes mellitus. Oftalmologicheskii Zhurnal, 2017, 66, 8-11.	0.0	2
20	Relationships between diabetic gastroparesis and risk of developing hypoglycemic conditions. Mìžnarodnij EndokrinologìÄnij Žurnal, 2017, 13, 143-149.	0.1	0
21	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	1.3	21
22	An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity. Obesity and Metabolism, 2016, 13, 49-53.	0.4	3
23	Serum levels of endothelial monocyte activating polypeptide-II in type 1 diabetes patients with microangyopathy and arterial hypertention Diabetes Mellitus, 2016, 19, 309-314.	0.5	4
24	The relationship between cognitive impairment and decreased cerebral blood flow in the frontal area. East European Journal of Neurology, 2016, , 26-29.	0.0	0
25	The INTERPRET–DD study of diabetes and depression: a protocol. Diabetic Medicine, 2015, 32, 925-934.	1.2	28
26	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	6.3	659
27	The Content of Blood Leptin and Activity of Systemic Inflammatory Response in Patients with Type 2 Diabetes Mellitus depending on Weight and Length of the Process. International Journal of Physiology and Pathophysiology, 2015, 6, 213-219.	0.1	1
28	Self-Monitoring of Blood Glucose in Diabetes: From Evidence to Clinical Reality in Central and Eastern Europe—Recommendations from the International Central-Eastern European Expert Group. Diabetes Technology and Therapeutics, 2014, 16, 460-475.	2.4	54
29	Antihypertensive Treatment and Kidney Function in Routine Practice in Patients with Type 2 Diabetes Mellitus: The Results of the Prospective "The Scythian" Trial in Ukraine. The Open Urology & Nephrology Journal, 2014, 7, 71-76.	0.2	1
30	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	13.9	2,261
31	Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine. Journal of Multidisciplinary Healthcare, 2013, 6, 249.	1.1	4
32	Morphology of bronchial epithelium in rodent streptozotocin-induced diabetes mellitus. Diabetes Mellitus, 2013, 16, 44-48.	0.5	0
33	Correlation between arterial wall stiffness, N-terminal prohormone of brain natriuretic peptide, functional and structural myocardial abnormalities in patients with type 2 diabetes mellitus and cardiac autonomic neuropathy. Diabetes Mellitus, 2013, 16, 72-77.	0.5	3
34	BLOOD PRESSURE AND KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: RESULTS OF THE PROSPECTIVE STUDY SKIF-2. Journal of Hypertension, 2011, 29, e233.	0.3	0
35	Is serum uric acid a risk factor for atherosclerotic cardiovascular disease?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2010, 4, 176-184.	1.8	14
36	Treatment of Symptomatic Polyneuropathy With Actovegin in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 1479-1484.	4.3	73

Boris Mankovsky

#	Article	IF	CITATIONS
37	Stroke and Diabetes Mellitus. , 2009, , 183-218.		1
38	Glitazones: Beyond glucose lowering!. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2007, 1, 197-207.	1.8	1
39	Stroke in patients with diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2004, 20, 268-287.	1.7	93
40	Impairment of cerebral autoregulation in diabetic patients with cardiovascular autonomic neuropathy and orthostatic hypotension. Diabetic Medicine, 2003, 20, 119-126.	1.2	79
41	Instability Of Cerebral Blood Flow In Diabetic Patients With Cardiovascular Autonomic Neuropathy And Orthostatic Hypotension. Journal of the Peripheral Nervous System, 2000, 5, 185-185.	1.4	0
42	The size of subcortical ischemic infarction in patients with and without diabetes mellitus. Clinical Neurology and Neurosurgery, 1996, 98, 137-141.	0.6	19
43	Cerebrovascular disorders in patients with diabetes mellitus. Journal of Diabetes and Its Complications, 1996, 10, 228-242.	1.2	116
44	The effect of metformin on spontaneous apoptosis in patients with type 2 diabetes. Endocrine Abstracts, 0, , .	0.0	0
45	Effects of statins on lipid and carbohydrate metabolism in patient with type 2 diabetes and cardiovascular diseases. Endocrine Abstracts, 0, , .	0.0	0
46	Risk factors for delay gastric emptying in patients with type 2 diabites. Endocrine Abstracts, 0, , .	0.0	0